Oppenheimer Maintains Their Buy Rating on Prevail Therapeutics (PRVL)

In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Prevail Therapeutics (PRVLResearch Report), with a price target of $25.25. The company’s shares closed last Monday at $15.85.

According to TipRanks.com, Olson has currently no stars on a ranking scale of 0-5 stars, with an average return of -10.9% and a 33.1% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, ACADIA Pharmaceuticals, and Enanta Pharmaceuticals.

Prevail Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $23.00, implying a 43.4% upside from current levels. In a report issued on March 6, Citigroup also initiated coverage with a Buy rating on the stock with a $24.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $19.25 and a one-year low of $7.41. Currently, Prevail Therapeutics has an average volume of 133.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The firm engages in the research and development of novel biologic gene therapies to treat Parkinson’s disease and other neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY.